Targeting MYC-driven lymphoma : lessons learned and future directions
Martínez-Martín, Sandra (Vall d'Hebron Institut d'Oncologia)
Beaulieu, Marie-Eve (Vall d'Hebron Institut d'Oncologia)
Soucek, Laura (Universitat Autònoma de Barcelona)

Data:	2023
Resum:	MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.
Ajuts:	Agencia Estatal de Investigación RTC2019-007067-1
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	High-grade B-cell lymphoma ; Double expressor lymphoma ; MYC ; MYC therapies
Publicat a:	Cancer Drug Resistance, Vol. 6 (april 2023) , p. 205-222, ISSN 2578-532X

DOI: 10.20517/cdr.2022.127
PMID: 37457123

18 p, 415.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats